Want to see PRLD full AI Analyst Report?
PRLD Stock Chart & Stats
$2.45
-$0.05(-4.55%)
At close: 4:00 PM EST
$2.45
-$0.05(-4.55%)
Day’s Range― - ―
52-Week Range$0.75 - $5.69
Previous CloseN/A
Volume107.75K
Average Volume (3M)256.05K
Market Cap
$407.78M
Enterprise Value$243.62M
Total Cash (Recent Filing)$81.55M
Total Debt (Recent Filing)$17.72M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Aug 19, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.06
Shares Outstanding64,917,175
10 Day Avg. Volume194,393
30 Day Avg. Volume256,051
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.25
Price to Sales (P/S)18.38
P/FCF Ratio-3.96
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue14.57
Enterprise Value/Gross Profit14.92
Enterprise Value/Ebitda-3.20
Forecast
1Y Price Target
$8.50Price Target Upside246.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.65
Revenue Forecast (FY)$22.76M
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPresentation of updated results from the Phase 1 trial evaluating PRT3789 in biomarker-selected SMARCA4-mutated cancers is expected to be a catalyst.
Financial PositionThe cash position of $133.6 million provides a strong financial foundation for Prelude Therapeutics.
Market PotentialPrelude Therapeutics shares represent a unique investment opportunity, with a potential upside of 646%.
Bears Say
Clinical RisksRisks include negative clinical results for PRT3789 and delays in advancing these candidates into registrational programs.
Competitive RisksThe competitive landscape poses risks, particularly with respect to other SMARCA2 inhibitors/degraders that are currently in clinical development.
Prelude Therapeutics News
PRLD FAQ
What was Prelude Therapeutics’s price range in the past 12 months?
Prelude Therapeutics lowest stock price was $0.75 and its highest was $5.69 in the past 12 months.
What is Prelude Therapeutics’s market cap?
Prelude Therapeutics’s market cap is $407.78M.
When is Prelude Therapeutics’s upcoming earnings report date?
Prelude Therapeutics’s upcoming earnings report date is Aug 19, 2026 which is in 40 days.
How were Prelude Therapeutics’s earnings last quarter?
Prelude Therapeutics released its earnings results on May 12, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.252 by $0.122.
Is Prelude Therapeutics overvalued?
According to Wall Street analysts Prelude Therapeutics’s price is currently Undervalued.
Does Prelude Therapeutics pay dividends?
Prelude Therapeutics does not currently pay dividends.
What is Prelude Therapeutics’s EPS estimate?
Prelude Therapeutics’s EPS estimate is -0.24.
How many shares outstanding does Prelude Therapeutics have?
Prelude Therapeutics has 64,917,175 shares outstanding.
What happened to Prelude Therapeutics’s price movement after its last earnings report?
Prelude Therapeutics reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.252. Following the earnings report the stock price went down -3.333%.
Which hedge fund is a major shareholder of Prelude Therapeutics?
Currently, no hedge funds are holding shares in PRLD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prelude Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.50 (246.94% Upside)
$8.50 (246.94% Upside)
Hedge Fund Trend
Increased
By 11.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $25.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 6.5%
Last 30 Days ▲ 6.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-38.02%
12-Months-Change
Fundamentals
Return on Equity
-118.24%
Trailing 12-Months
Asset Growth
-15.30%
Trailing 12-Months
Company Description
Prelude Therapeutics
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
PRLD Stock 12 Month Forecast
Average Price Target
$8.50
▲(246.94% Upside)
Technical Analysis
Ownership Overview
36.92% Insiders
2.39% Mutual Funds
37.60% Other Institutional Investors
19.54% Public Companies and
Individual Investors